SCHEMBL4846394

SCHEMBL4846394

CCOC(=O)C1CCN(c2nc(COc3ccc(COc4nn(-c5ccccc5)cc4C=O)cc3OC)c(C)s2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.40
MEN1 O00255 6/20 0.40
KMT2A Q03164 6/20 0.40
ATM Q13315 2/20 0.40
TP53 P04637 3/20 0.39
GAA P10253 2/20 0.39
MAPT P10636 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TSHR P16473 2/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
MAPK1 P28482 2/20 0.38
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
KDM4E B2RXH2 4/20 0.37
F2 P00734 1/20 0.36
F10 P00742 1/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4847940 0.90 ALDH1A1 (0.36) ALDH1A1MEN1KMT2AATMTP53
SCHEMBL4847933 0.90 ALDH1A1 (0.36) ALDH1A1MEN1KMT2AATMTP53
SCHEMBL4845749 0.88 ALDH1A1 (0.40) ALDH1A1MEN1KMT2ATP53GAA
SCHEMBL4850499 0.86 F2RL3 (0.42) MEN1KMT2ATP53GAAMAPT
SCHEMBL4854097 0.85 TP53 (0.35) ALDH1A1MEN1KMT2ATP53GAA
SCHEMBL4854119 0.85 TP53 (0.35) ALDH1A1MEN1KMT2ATP53GAA
SCHEMBL4845618 0.81 ALDH1A1 (0.51) ALDH1A1MEN1KMT2AATMTP53
SCHEMBL4848592 0.80 F2RL3 (0.42) ALDH1A1MEN1KMT2AGAAMAPT
SCHEMBL4851672 0.80 MAPK1 (0.48) ALDH1A1MEN1KMT2AATMTP53
SCHEMBL4852283 0.80 ALDH1A1 (0.50) ALDH1A1MEN1KMT2AATMTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368578-B2 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-06 US disclosed
US-20060135578-A1 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 US disclosed
EP-1541564-A1 FIVE-MEMBERED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135578-A1 Five-membered heterocyclic compounds GPR119, OR10J3, CYP11B1 ALDH1A1 821/4885MEN1 3268/4885KMT2A 1792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.